Oramed Receives $50M Investment From Largest Chinese Pharmaceutical

December 1, 2015 | Following a string of Chinese investments into Israeli companies, Hefei Tianhui Incubator of Technologies (HTIT) has invested $50 million in Israeli biomedical company Oramed in exchange for exclusive rights to market Oramed’s oral insulin capsule, ORMD-0801, in China, Hong Kong and Macau. HTIT is partially owned by Sinopharm Group, the largest pharmaceutical company in China, which currently has the largest population of people living with diabetes. Founded in 2006 and led by CEO Nadav Kidron, Oramed has developed a method for oral delivery of drugs which currently are only administered via injection. The company is traded on the Nasdaq with a current market cap of $89.90M